Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lapatinib - Novartis

Drug Profile

Lapatinib - Novartis

Alternative Names: 572016; Cipatinib; GSK-572016; GW 572016; GW-2016; GW-572016F; Lapatinib - GlaxoSmithKline; Lapatinib ditosilate; Lapatinib ditosylate; Tykerb; Tyverb

Latest Information Update: 28 May 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GlaxoSmithKline
  • Developer Beth Israel Deaconess Medical Center; Eddingpharm; FONDAZIONE DEL PIEMONTE PER L'ONCOLOGIA IRCC DI CANDIOLO; GlaxoSmithKline; National Taiwan University Hospital; Novartis; West German Study Group
  • Class Antineoplastics; Chlorobenzenes; Fluorobenzenes; Furans; Phenyl ethers; Quinazolines; Small molecules; Sulfones
  • Mechanism of Action Epidermal growth factor receptor antagonists; ERBB 2 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Breast cancer
  • Phase III Brain metastases
  • Phase II/III Bladder cancer
  • Phase II Colorectal cancer; Non-small cell lung cancer
  • Discontinued Gastric cancer; Head and neck cancer; Prostate cancer

Most Recent Events

  • 08 Apr 2022 Pharmacodynamics data from a phase III Neo ALTTO trial in Breast cancer presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)
  • 31 Jan 2022 Phase-III clinical development ongoing in Breast cancer (Adjunctive treatment, First-line therapy, Metastatic disease) in Ukraine, Thailand, Russia, Peru, Pakistan, China, Hong Kong, Brazil (PO) (NCT00281658)
  • 07 Dec 2021 Pharmacodynamics data from a phase III Neo ALTTO trial in Breast cancer presented at the 44th Annual San Antonio Breast Cancer Symposium (SABCS-2021)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top